Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
Over the last decade, the multiple myeloma treatment landscape has rapidly evolved. While scientific innovation and the emergence of new therapies have helped provide a renewed sense of hope to people living with multiple myeloma, it has also made navigating the treatment journey more complex.
If you are a journalist or member of the media looking for Takeda Oncology resources, visit the media materials section of our newsroom.
For other Takeda news releases, please visit the Takeda.com Newsroom.
For media inquiries or reporter requests for more information, contact Oncology Communications via [email protected] If you generally would like to contact us, please visit Contact Us.